71 results
8-K
EX-99.2
GRTX
Galera Therapeutics Inc
12 May 20
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides
7:05am
and financial position, business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective product … was expected to enroll up to 70 patients and contribute to the safety database for avasopasem for SOM in HNC. As a result, in order to maintain the size
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
8 Sep 21
Regulation FD Disclosure
7:09am
of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current … . Phase 1 Next Anticipated Milestone IMRT induced Severe Oral Mucositis1 1EUSOM is a single-arm multi-center trial evaluating the safety and efficacy
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
10 Nov 20
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
7:07am
in hand, coupled with the preliminary safety findings of the combination, we look forward to continuing to advance the potential of our dismutase … in the second half of 2021.”
Third Quarter 2020 and Recent Corporate Highlights
In October, presented interim efficacy and safety data from
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
12 May 20
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides
7:05am
safety database, and are updating our guidance for completing enrollment to the first half of 2021 and for reporting topline data to the second half … of our pipeline in addressing radiation toxicities and improving the anti-cancer effect of radiation while prioritizing the health and safety of our
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
6 Jan 21
Regulation FD Disclosure
7:05am
results of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential … , business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective product candidates, plans
8-K
EX-99.1
44e6d6
14 Jul 20
Regulation FD Disclosure
7:02am
8-K
EX-99.2
8ebh1q7rfx haz4
10 Nov 20
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
7:07am
8-K
EX-99.1
6vtdfgry7ys wl
16 Sep 20
Regulation FD Disclosure
8:06am
8-K
EX-99.1
ekye sbkrn3qc
28 Apr 21
Regulation FD Disclosure
12:00am
8-K
EX-99.1
u1d d7u16wxahljwl
9 Sep 20
Regulation FD Disclosure
7:01am
8-K
EX-99.2
ti61ja
26 Oct 22
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
1:41pm
8-K
EX-99.2
hbv6qg
14 Dec 21
Galera Announces Primary Endpoint Met Statistical Significance in Corrected
7:06am
8-K
EX-99.1
pxtxk8gzvwsbw sm
10 Aug 20
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
7:10am
8-K
EX-99.1
qtltvy 95w2gezl
10 Aug 23
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
8:00am